Pharmaceutical

MSD receives FDA approval for Enflonsia to prevent RSV

MSD has received FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) in neonates and infants.

Jun 11, 2025 - 06:00
MSD receives FDA approval for Enflonsia to prevent RSV
MSD has received FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) in neonates and infants.
Read the original article

Tags:

Previous Article

RFK Jr axes vaccine advisory committee members

Next Article

EC approves Alnylam’s vutrisiran for ATTR-CM treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT’s Inaugural Diversity Report and Commitment to a Workplace of Diversity and Inclusion

STAT’s Inaugural Diversity Report and Commitment to a W...

Jul 6, 2023

Opinion: Smoke from Canadian wildfires shows outdoor workers need air quality protections

Opinion: Smoke from Canadian wildfires shows outdoor wo...

Jun 28, 2023

NPX-267 by NextPoint Therapeutics for Osteosarcoma: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Osteosarcoma: Lik...

Jun 14, 2024